

# Neal L Benowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8158694/publications.pdf>

Version: 2024-02-01

364  
papers

34,007  
citations

3933

88  
h-index

4432

172  
g-index

368  
all docs

368  
docs citations

368  
times ranked

20748  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biochemical verification of tobacco use and cessation. <i>Nicotine and Tobacco Research</i> , 2002, 4, 149-159.	2.6	1,670
2	Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. <i>Tobacco Control</i> , 2014, 23, 133-139.	3.2	1,324
3	Metabolism and Disposition Kinetics of Nicotine. <i>Pharmacological Reviews</i> , 2005, 57, 79-115.	16.0	1,298
4	Nicotine Addiction. <i>New England Journal of Medicine</i> , 2010, 362, 2295-2303.	27.0	1,196
5	Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. <i>Handbook of Experimental Pharmacology</i> , 2009, , 29-60.	1.8	1,045
6	E-Cigarettes. <i>Circulation</i> , 2014, 129, 1972-1986.	1.6	1,031
7	Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet</i> , The, 2016, 387, 2507-2520.	13.7	929
8	Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2009, 49, 57-71.	9.4	664
9	Drug Interactions with Tobacco Smoking. <i>Clinical Pharmacokinetics</i> , 1999, 36, 425-438.	3.5	562
10	Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 23-28.	4.7	544
11	Optimal Serum Cotinine Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different Racial/Ethnic Groups in the United States Between 1999 and 2004. <i>American Journal of Epidemiology</i> , 2009, 169, 236-248.	3.4	544
12	Establishing a Nicotine Threshold for Addiction – The Implications for Tobacco Regulation. <i>New England Journal of Medicine</i> , 1994, 331, 123-125.	27.0	459
13	Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. <i>Addiction</i> , 2014, 109, 1801-1810.	3.3	446
14	Cotinine disposition and effects. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 604-611.	4.7	434
15	Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. <i>Biomedical Applications</i> , 1981, 222, 61-70.	1.7	426
16	Metabolism of nicotine to cotinine studied by a dual stable isotope method. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 483-493.	4.7	415
17	Female sex and oral contraceptive use accelerate nicotine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 480-488.	4.7	396
18	Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 64-72.	4.7	366

#	ARTICLE	IF	CITATIONS
19	Electronic Cigarettes. <i>Circulation</i> , 2014, 130, 1418-1436.	1.6	348
20	Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease. <i>Circulation</i> , 2010, 121, 221-229.	1.6	336
21	Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. <i>Progress in Cardiovascular Diseases</i> , 2003, 46, 91-111.	3.1	335
22	Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1086-1097.	2.6	325
23	Randomized Trial of Reduced-Nicotine Standards for Cigarettes. <i>New England Journal of Medicine</i> , 2015, 373, 1340-1349.	27.0	312
24	Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 515-523.	4.9	301
25	Risks and Benefits of Nicotine to Aid Smoking Cessation in Pregnancy. <i>Drug Safety</i> , 2001, 24, 277-322.	3.2	286
26	Circadian blood nicotine concentrations during cigarette smoking. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 758-764.	4.7	272
27	Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. <i>American Journal of Medicine</i> , 2008, 121, S3-S10.	1.5	267
28	Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 131-138.	10.7	247
29	Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 600-608.	4.7	242
30	Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. <i>Nicotine and Tobacco Research</i> , 2017, 19, 160-167.	2.6	234
31	Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: Absence of an isotope effect in the clearance of (S)-nicotine-3- <sup>2</sup> H <sub>2</sub> in humans. <i>Biological Mass Spectrometry</i> , 1991, 20, 247-252.	0.5	219
32	2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3332-3365.	2.8	219
33	Clinical Pharmacokinetics of Lignocaine. <i>Clinical Pharmacokinetics</i> , 1978, 3, 177-201.	3.5	213
34	Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 316-323.	4.7	213
35	Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. <i>Addiction</i> , 2016, 111, 535-544.	3.3	204
36	Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 87-98.	4.7	203

#	ARTICLE	IF	CITATIONS
37	Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine*. Clinical Pharmacology and Therapeutics, 1997, 62, 453-463.	4.7	203
38	Mentholated Cigarette Smoking Inhibits Nicotine Metabolism. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1208-1215.	2.5	201
39	Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study. Pharmacology Biochemistry and Behavior, 2009, 92, 6-11.	2.9	200
40	Cardiovascular effects of electronic cigarettes. Nature Reviews Cardiology, 2017, 14, 447-456.	13.7	197
41	Slower Metabolism and Reduced Intake of Nicotine From Cigarette Smoking in Chinese-Americans. Journal of the National Cancer Institute, 2002, 94, 108-115.	6.3	192
42	The Past, Present, and Future of Nicotine Addiction Therapy. Annual Review of Medicine, 2016, 67, 467-486.	12.2	192
43	Nicotine Blood Levels and Subjective Craving for Cigarettes. Pharmacology Biochemistry and Behavior, 2000, 66, 553-558.	2.9	190
44	E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L135-L144.	2.9	187
45	Determination of the nicotine metabolites cotinine and trans-3-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: Biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 267-276.	2.3	185
46	CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology and Therapeutics, 2006, 80, 457-467.	4.7	184
47	Clinical Pharmacology and Toxicology of Cocaine. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 3-12.	0.0	179
48	Thirdhand Smoke: New Evidence, Challenges, and Future Directions. Chemical Research in Toxicology, 2017, 30, 270-294.	3.3	178
49	Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes. Journal of the American College of Cardiology, 2015, 66, 1378-1391.	2.8	164
50	Determinants of nicotine intake while chewing nicotine polacrilex gum. Clinical Pharmacology and Therapeutics, 1987, 41, 467-473.	4.7	163
51	Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine and Tobacco Research, 2003, 5, 621-624.	2.6	163
52	The Regulatory Challenge of Electronic Cigarettes. JAMA - Journal of the American Medical Association, 2013, 310, 685.	7.4	150
53	Balancing Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health, 2021, 111, 1661-1672.	2.7	150
54	Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clinical Pharmacology and Therapeutics, 1975, 18, 287-297.	4.7	142

#	ARTICLE	IF	CITATIONS
55	Sympathomimetic effects of paraxanthine and caffeine in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 684-691.	4.7	139
56	Clonidine for smoking cessation. The Cochrane Library, 2004, , CD000058.	2.8	138
57	Reducing the nicotine content to make cigarettes less addictive. Tobacco Control, 2013, 22, i14-i17.	3.2	136
58	Nicotine Replacement Therapy. Drugs, 1993, 45, 157-170.	10.9	135
59	IQOS: examination of Philip Morris International's claim of reduced exposure. Tobacco Control, 2018, 27, s30-s36.	3.2	135
60	Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clinical Pharmacology and Therapeutics, 1993, 53, 529-535.	4.7	132
61	Smoking Behavior and Exposure to Tobacco Toxicants during 6 Months of Smoking Progressively Reduced Nicotine Content Cigarettes. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 761-769.	2.5	132
62	Elimination Kinetics of the Tobacco-Specific Biomarker and Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3421-3425.	2.5	131
63	Nicotine and Carcinogen Exposure with Smoking of Progressively Reduced Nicotine Content Cigarette. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2479-2485.	2.5	130
64	Comparison of Urine Cotinine and the Tobacco-Specific Nitrosamine Metabolite 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) and Their Ratio to Discriminate Active From Passive Smoking. Nicotine and Tobacco Research, 2011, 13, 202-208.	2.6	129
65	Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes. Pediatrics, 2018, 141, .	2.1	129
66	Comparison of Nicotine and Carcinogen Exposure with Water Pipe and Cigarette Smoking. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 765-772.	2.5	128
67	Cigarette Smoke Toxins Deposited on Surfaces: Implications for Human Health. PLoS ONE, 2014, 9, e86391.	2.5	125
68	Pharmacokinetics in Patients with Cardiac Failure. Clinical Pharmacokinetics, 1976, 1, 389-405.	3.5	121
69	Stable isotope studies of nicotine kinetics and bioavailability. Clinical Pharmacology and Therapeutics, 1991, 49, 270-277.	4.7	119
70	Nicotine, Carbon Monoxide, and Carcinogen Exposure after a Single Use of a Water Pipe. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2345-2353.	2.5	113
71	Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. JAMA - Journal of the American Medical Association, 2018, 320, 880.	7.4	113
72	Current advances in research in treatment and recovery: Nicotine addiction. Science Advances, 2019, 5, eaay9763.	10.3	112

#	ARTICLE	IF	CITATIONS
73	Pharmacotherapy for smoking cessation during pregnancy. <i>Nicotine and Tobacco Research</i> , 2004, 6, 189-202.	2.6	109
74	Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. <i>JAMA Internal Medicine</i> , 2018, 178, 622.	5.1	108
75	Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 99-109.	4.7	106
76	Changes in rate and pattern of caffeine metabolism after cigarette abstinence. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 488-491.	4.7	105
77	Racial Differences in the Relationship Between Number of Cigarettes Smoked and Nicotine and Carcinogen Exposure. <i>Nicotine and Tobacco Research</i> , 2011, 13, 772-783.	2.6	105
78	Gender differences in the pharmacology of nicotine addiction. <i>Addiction Biology</i> , 1998, 3, 383-404.	2.6	104
79	Subpicogram per Milliliter Determination of the Tobacco-Specific Carcinogen Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Human Urine Using Liquid Chromatography~Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2008, 80, 8115-8121.	6.5	104
80	Nicotine intake and dose response when smoking reduced~nicotine content cigarettes. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 703-714.	4.7	101
81	Nicotine Metabolite Ratio Predicts Smoking Topography and Carcinogen Biomarker Level. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 234-238.	2.5	101
82	Dose-dependency of caffeine metabolism with repeated dosing. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 277-285.	4.7	100
83	Cardiovascular Effects of Nasal and Transdermal Nicotine and Cigarette Smoking. <i>Hypertension</i> , 2002, 39, 1107-1112.	2.7	100
84	Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1105-1114.	2.5	96
85	Biomarkers of exposure to new and emerging tobacco delivery products. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L425-L452.	2.9	95
86	The Effect of Cigarette Smoking on Penile Erection. <i>Journal of Urology</i> , 1987, 138, 438-441.	0.4	94
87	Cardiovascular effects of intravenous delta~tetrahydrocannabinol: Autonomic nervous mechanisms. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 440-446.	4.7	93
88	Nicotine metabolism and elimination kinetics in newborns. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 458-465.	4.7	91
89	Reduced Tar, Nicotine, and Carbon Monoxide Exposure While Smoking Ultralow- but Not Low-Yield Cigarettes. <i>JAMA - Journal of the American Medical Association</i> , 1986, 256, 241.	7.4	88
90	Carcinogen Exposure during Short-term Switching from Regular to "Light" Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1376-1383.	2.5	88

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 6-14.	4.7	86
92	Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. <i>Nicotine and Tobacco Research</i> , 2009, 11, 954-960.	2.6	86
93	Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 468-474.	4.7	85
94	Emissions from Electronic Cigarettes: Assessing Vapers' Intake of Toxic Compounds, Secondhand Exposures, and the Associated Health Impacts. <i>Environmental Science &amp; Technology</i> , 2017, 51, 9271-9279.	10.0	85
95	Characterization of Nicotine Salts in 23 Electronic Cigarette Refill Liquids. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1239-1243.	2.6	85
96	Impact of e-liquid flavors on nicotine intake and pharmacology of e-cigarettes. <i>Drug and Alcohol Dependence</i> , 2017, 178, 391-398.	3.2	83
97	Poisoning Due to Class IA Antiarrhythmic Drugs Quinidine, Procainamide and Disopyramide. <i>Drug Safety</i> , 1990, 5, 393-420.	3.2	79
98	Dose-related cardiovascular and endocrine effects of transdermal nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 87-95.	4.7	79
99	Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	79
100	Prevalence of Smoking Assessed Biochemically in an Urban Public Hospital: A Rationale for Routine Cotinine Screening. <i>American Journal of Epidemiology</i> , 2009, 170, 885-891.	3.4	78
101	Stable isotope method for studying transdermal drug absorption: The nicotine patch. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 286-293.	4.7	77
102	Disposition kinetics and effects of menthol. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 128-135.	4.7	77
103	The Ability of Plasma Cotinine to Predict Nicotine and Carcinogen Exposure is Altered by Differences in CYP2A6: the Influence of Genetics, Race, and Sex. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 708-718.	2.5	77
104	Urine Nicotine Metabolites and Smoking Behavior in a Multiracial/Multiethnic National Sample of Young Adults. <i>American Journal of Epidemiology</i> , 2007, 165, 901-910.	3.4	76
105	Bupropion for Smoking Cessation in African American Light Smokers: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 290-298.	6.3	74
106	Emerging Nicotine Delivery Products. Implications for Public Health. <i>Annals of the American Thoracic Society</i> , 2014, 11, 231-235.	3.2	74
107	Genetic and environmental influences on the ratio of 3-hydroxycotinine to cotinine in plasma and urine. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 388-398.	1.5	72
108	Nicotine Delivery and Vaping Behavior during <i>ad libitum</i> E-cigarette Access. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 363-376.	0.2	71

#	ARTICLE	IF	CITATIONS
109	Poisoning Due to Calcium Antagonists. Drug Safety, 1991, 6, 408-430.	3.2	70
110	Nicotine and Carcinogen Exposure after Water Pipe Smoking in Hookah Bars. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1055-1066.	2.5	70
111	Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenetics and Genomics, 2005, 15, 115-125.	1.5	68
112	Cytisine for smoking cessation: A research agenda. Drug and Alcohol Dependence, 2008, 92, 3-8.	3.2	68
113	Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. Journal of Clinical Psychopharmacology, 2019, 39, 108-116.	1.4	67
114	Pharmacokinetics of Haemoperfusion for Drug Overdose. Clinical Pharmacokinetics, 1979, 4, 329-354.	3.5	66
115	Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1239-1246.	2.5	65
116	Dietary supplement adverse events: Report of a one-year poison center surveillance project. Journal of Medical Toxicology, 2008, 4, 84-92.	1.5	64
117	Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction, 2019, 114, 1951-1969.	3.3	63
118	Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clinical Pharmacology and Therapeutics, 1980, 28, 115-120.	4.7	62
119	Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clinical Pharmacology and Therapeutics, 2000, 67, 653-659.	4.7	61
120	Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. Preventive Medicine, 2014, 68, 17-22.	3.4	61
121	Is Clonidine an Effective Smoking Cessation Therapy?. Drugs, 1995, 50, 197-207.	10.9	60
122	Within-Subject Variation of the Salivary 3HC/COT Ratio in Regular Daily Smokers: Prospects for Estimating CYP2A6 Enzyme Activity in Large-Scale Surveys of Nicotine Metabolic Rate. Journal of Analytical Toxicology, 2006, 30, 386-389.	2.8	60
123	Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control, 2022, 31, e88-e93.	3.2	60
124	Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction, 2018, 113, 1507-1516.	3.3	58
125	Dual Users Compared to Smokers: Demographics, Dependence, and Biomarkers. Nicotine and Tobacco Research, 2019, 21, 1279-1284.	2.6	58
126	Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1668-73.	2.5	58



#	ARTICLE	IF	CITATIONS
127	Children's Exposure to Secondhand and Thirdhand Smoke Carcinogens and Toxicants in Homes of Hookah Smokers. <i>Nicotine and Tobacco Research</i> , 2014, 16, 961-975.	2.6	57
128	Pharmacokinetics of Drug Overdose. <i>Clinical Pharmacokinetics</i> , 1981, 6, 161-192.	3.5	56
129	Rate of Nicotine Metabolism and Withdrawal Symptoms in Adolescent Light Smokers. <i>Pediatrics</i> , 2008, 122, e643-e647.	2.1	56
130	Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in Total Duration of Ischaemic Events [IDIE]) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 55, 107, 145-150.	1.6	56
131	Prevention and Treatment of Tobacco Use. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1030-1045.	2.8	56
132	Deficient C-oxidation of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 590-594.	4.7	55
133	Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 135-141.	1.5	55
134	E-cigarette Dependence Measures in Dual Users: Reliability and Relations With Dependence Criteria and E-cigarette Cessation. <i>Nicotine and Tobacco Research</i> , 2020, 22, 756-763.	2.6	55
135	Effect of Pod e-Cigarettes vs Cigarettes on Carcinogen Exposure Among African American and Latinx Smokers. <i>JAMA Network Open</i> , 2020, 3, e2026324.	5.9	55
136	Cardiovascular and Metabolic Considerations in Prolonged Cannabinoid Administration in Man. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 214S-223S.	2.0	54
137	Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes. <i>Nicotine and Tobacco Research</i> , 2018, 20, ntw333.	2.6	54
138	Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstinence. <i>Cancer Prevention Research</i> , 2020, 13, 153-162.	1.5	54
139	Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 474-479.	4.7	53
140	Thirdhand smoke contamination in hospital settings: assessing exposure risk for vulnerable paediatric patients: Table A1. <i>Tobacco Control</i> , 2016, 25, 619-623.	3.2	53
141	Impact of e-liquid flavors on e-cigarette vaping behavior. <i>Drug and Alcohol Dependence</i> , 2018, 189, 42-48.	3.2	53
142	Changes in Use Patterns Over 1 Year Among Smokers and Dual Users of Combustible and Electronic Cigarettes. <i>Nicotine and Tobacco Research</i> , 2020, 22, 672-680.	2.6	53
143	Compensatory Smoking from Gradual and Immediate Reduction in Cigarette Nicotine Content. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 472-476.	2.5	52
144	Factors That Explain Differences in Abstinence Between Black and White Smokers: A Prospective Intervention Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1078-1087.	6.3	52

#	ARTICLE	IF	CITATIONS
145	Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 1-7.	2.9	51
146	Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism Antipyrine, pentobarbital, and ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 259-268.	4.7	50
147	Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2000, 23, 653-661.	2.8	50
148	Cotinine effects on nicotine metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 649-654.	4.7	49
149	Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017, 19, 59-67.	2.6	49
150	Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 183-188.	4.7	48
151	Mouth versus deep airways absorption of nicotine in cigarette smokers. <i>Pharmacology Biochemistry and Behavior</i> , 1986, 25, 1181-1184.	2.9	48
152	Prolonged absorption with development of tolerance to toxic effects after cutaneous exposure to nicotine. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 119-120.	4.7	48
153	A Comparison of Nicotine Biomarkers and Smoking Patterns in Daily and Nondaily Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1264-1272.	2.5	48
154	Cardiovascular Effects of Hookah Smoking: Potential Implications for Cardiovascular Risk. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1151-1161.	2.6	47
155	Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flowâ€“limited percutaneous absorption. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 223-230.	4.7	46
156	Estimation of Nicotine Dose after Low-level Exposure Using Plasma and Urine Nicotine Metabolites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1160-1166.	2.5	46
157	Individual differences in nicotine intake per cigarette. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 468-71.	2.5	46
158	Propranolol antagonism of phenylpropanolamine-induced hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 488-494.	4.7	45
159	Chronopharmacokinetics of nicotine*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 385-395.	4.7	45
160	Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. <i>Carcinogenesis</i> , 2013, 34, 93-101.	2.8	45
161	Genomeâ€“wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. <i>Addiction</i> , 2018, 113, 509-523.	3.3	45
162	Evaluating the temporal relationships between withdrawal symptoms and smoking relapse.. <i>Psychology of Addictive Behaviors</i> , 2019, 33, 105-116.	2.1	45

#	ARTICLE	IF	CITATIONS
163	The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients. <i>Drugs and Aging</i> , 1996, 9, 8-23.	2.7	44
164	Estimations and predictors of non-€ compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016, 111, 2208-2216.	3.3	44
165	Thirdhand Smoke: State of the Science and a Call for Policy Expansion. <i>Public Health Reports</i> , 2016, 131, 233-238.	2.5	43
166	Exposure to polycyclic aromatic hydrocarbons and volatile organic compounds among recently pregnant rural Guatemalan women cooking and heating with solid fuels. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 726-735.	4.3	42
167	JUUL electronic cigarettes: Nicotine exposure and the user experience. <i>Drug and Alcohol Dependence</i> , 2019, 203, 83-87.	3.2	42
168	Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 139-143.	4.7	41
169	Cytisine, the world's oldest smoking cessation aid. <i>BMJ, The</i> , 2013, 347, f5198-f5198.	6.0	41
170	Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game. <i>Addiction</i> , 2017, 112, 6-7.	3.3	41
171	Comparison of Urine 4-(Methylnitrosamino)-1-(3)Pyridyl-1-Butanol and Cotinine for Assessment of Active and Passive Smoke Exposure in Urban Adolescents. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 254-261.	2.5	41
172	Methadone-€ Disulfiram Interaction During Methadone Maintenance. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 506-513.	2.0	40
173	Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. <i>PLoS ONE</i> , 2015, 10, e0128109.	2.5	40
174	Validity of self-reported adult secondhand smoke exposure. <i>Tobacco Control</i> , 2015, 24, 48-53.	3.2	40
175	Tobacco Alkaloids and Tobacco-Specific Nitrosamines in Dust from Homes of Smokeless Tobacco Users, Active Smokers, and Nontobacco Users. <i>Chemical Research in Toxicology</i> , 2015, 28, 1007-1014.	3.3	40
176	Pharmacodynamics of nicotine: implications for rational treatment of nicotine addiction. <i>Addiction</i> , 1991, 86, 495-499.	3.3	39
177	Non-Nicotine Pharmacotherapy for Smoking Cessation. <i>CNS Drugs</i> , 2000, 13, 265-285.	5.9	39
178	CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 429-440.	1.5	39
179	Variation in Trans-3-€ <sup>2</sup> -Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake. <i>PLoS ONE</i> , 2013, 8, e70938.	2.5	39
180	Urine Menthol as a Biomarker of Mentholated Cigarette Smoking. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3013-3019.	2.5	38

#	ARTICLE	IF	CITATIONS
181	Urine Cotinine Underestimates Exposure to the Tobacco-Derived Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Passive Compared with Active Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2795-2800.	2.5	37
182	Nicotelline: A Proposed Biomarker and Environmental Tracer for Particulate Matter Derived from Tobacco Smoke. <i>Chemical Research in Toxicology</i> , 2013, 26, 1615-1631.	3.3	37
183	Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1837-1844.	2.6	37
184	Effect of e-cigarette flavors on nicotine delivery and puffing topography: results from a randomized clinical trial of daily smokers. <i>Psychopharmacology</i> , 2020, 237, 491-502.	3.1	37
185	Pharmacokinetic Considerations in Understanding Nicotine Dependence. <i>Novartis Foundation Symposium</i> , 1990, 152, 186-209.	1.1	37
186	Pharmacokinetic and Pharmacodynamic Considerations in Drug Therapy of Cardiac Emergencies. <i>Clinical Pharmacokinetics</i> , 1984, 9, 273-308.	3.5	36
187	Additive cardiovascular effects of nicotine and ethanol. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 40, 420-424.	4.7	36
188	Effects of passive smoking on theophylline clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 399-407.	4.7	36
189	An Electronic Cigarette Vaping Machine for the Characterization of Aerosol Delivery and Composition. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw147.	2.6	36
190	E-Cigarettes and Cardiopulmonary Health. <i>Function</i> , 2021, 2, zqab004.	2.3	36
191	Pharmacoepidemiology of the effect of caffeine on blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 57-60.	4.7	35
192	Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 284-296.	4.7	35
193	Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. <i>Addiction</i> , 2013, 108, 607-617.	3.3	35
194	Intake of Toxic and Carcinogenic Volatile Organic Compounds from Secondhand Smoke in Motor Vehicles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2774-2782.	2.5	35
195	The Threat of Menthol Cigarettes to U.S. Public Health. <i>New England Journal of Medicine</i> , 2011, 364, 2179-2181.	27.0	34
196	Saliva cotinine levels as a function of collection method. <i>Addiction</i> , 1997, 92, 347-351.	3.3	33
197	Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. <i>Addictive Behaviors</i> , 2013, 38, 1796-1803.	3.0	33
198	Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. <i>Addiction</i> , 2015, 110, 1667-1675.	3.3	33

#	ARTICLE	IF	CITATIONS
199	Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking. <i>Nicotine and Tobacco Research</i> , 2020, 22, 288-292.	2.6	33
200	Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 55-64.	4.7	32
201	Environmental and Drug-Induced Hyperthermia Pathophysiology, Recognition, Management. <i>Emergency Medicine Clinics of North America</i> , 1984, 2, 459-474.	1.2	32
202	Measures and predictors of varenicline adherence in the treatment of nicotine dependence. <i>Addictive Behaviors</i> , 2017, 75, 122-129.	3.0	31
203	Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users. <i>Addiction</i> , 2020, 115, 757-767.	3.3	31
204	Prolonged delta-9-tetrahydrocannabinol ingestion; Effects of sympathomimetic amines and autonomic blockades. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 336-342.	4.7	30
205	Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1988, 25, 1117-1128.	1.0	30
206	Progressive Commercial Cigarette Yield Reduction: Biochemical Exposure and Behavioral Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 876-883.	2.5	30
207	Disposition kinetics and metabolism of nicotine and cotinine in African American smokers. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 340-350.	1.5	30
208	Early exposure to thirdhand cigarette smoke affects body mass and the development of immunity in mice. <i>Scientific Reports</i> , 2017, 7, 41915.	3.3	30
209	Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health. <i>Preventive Medicine</i> , 2018, 117, 8-14.	3.4	30
210	Short-term early exposure to thirdhand cigarette smoke increases lung cancer incidence in mice. <i>Clinical Science</i> , 2018, 132, 475-488.	4.3	30
211	Secondhand smoke exposure and asthma outcomes among African-American and Latino children with asthma. <i>Thorax</i> , 2018, 73, 1041-1048.	5.6	30
212	Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes. <i>Tobacco Regulatory Science</i> (discontinued), 2016, 2, 186-203.	0.2	29
213	Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. <i>Psychopharmacology</i> , 1998, 137, 383-390.	3.1	28
214	Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 641-651.	4.7	28
215	Cigarette Smoking Sensitizes and Desensitizes Impedance-measured ADP-induced Platelet Aggregation in Whole Blood. <i>Thrombosis and Haemostasis</i> , 1995, 74, 730-735.	3.4	28
216	Poisoning Due to Class 1B Antiarrhythmic Drugs. <i>Medical Toxicology and Adverse Drug Experience</i> , 1989, 4, 412-428.	0.8	27

#	ARTICLE	IF	CITATIONS
217	High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine: A Proof of Concept Placebo-Controlled Trial. <i>Nicotine and Tobacco Research</i> , 2013, 15, 348-354.	2.6	27
218	Multiple risk-behavior profiles of smokers with serious mental illness and motivation for change.. <i>Health Psychology</i> , 2014, 33, 1518-1529.	1.6	27
219	<i>UGT1A</i> and <i>UGT2B</i> Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 94-104.	2.5	27
220	Electronic cigarette chemicals transfer from a vape shop to a nearby business in a multiple-tenant retail building. <i>Tobacco Control</i> , 2019, 28, 519-525.	3.2	27
221	Urine Cotinine Screening Detect Nearly Ubiquitous Tobacco Smoke Exposure in Urban Adolescents. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw390.	2.6	26
222	Randomized withinâ€subject trial to evaluate smokersâ€™ initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products. <i>Addiction</i> , 2019, 114, 1236-1248.	3.3	26
223	Effect of disulfiram on adrenergic function. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 469-475.	4.7	25
224	Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 352-362.	0.2	25
225	Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. <i>Addiction Biology</i> , 2020, 25, e12741.	2.6	25
226	Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. <i>Psychiatric Services</i> , 2021, 72, 7-15.	2.0	25
227	Assessment of Racial Differences in Pharmacotherapy Efficacy for Smoking Cessation. <i>JAMA Network Open</i> , 2021, 4, e2032053.	5.9	25
228	The effect of liver disease on urine caffeine metabolite ratios*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 624-635.	4.7	24
229	Stability of the Nicotine Metabolite Ratio in Smokers of Progressively Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1939-1942.	2.6	24
230	Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1971-1977.	3.3	24
231	Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers. <i>Drug and Alcohol Dependence</i> , 2016, 163, 157-164.	3.2	24
232	Orthostatic Hypertension Due to Vascular Adrenergic Hypersensitivity. <i>Hypertension</i> , 1996, 28, 42-46.	2.7	24
233	Biochemical Estimation of Noncompliance with Smoking of Very Low Nicotine Content Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 331-335.	2.5	23
234	The Influence of Puff Characteristics, Nicotine Dependence, and Rate of Nicotine Metabolism on Daily Nicotine Exposure in African American Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 936-943.	2.5	23

#	ARTICLE	IF	CITATIONS
235	Tobacco use disorder and cardiovascular health. <i>Addiction</i> , 2022, 117, 1128-1138.	3.3	23
236	Exposure to Toxicants Associated With Use and Transitions Between Cigarettes, e-Cigarettes, and No Tobacco. <i>JAMA Network Open</i> , 2022, 5, e2147891.	5.9	22
237	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1638-1646.	2.6	21
238	Resin hemoperfusion in ethchlorvynol overdose. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 236-242.	4.7	20
239	Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. <i>PLoS ONE</i> , 2015, 10, e0126113.	2.5	20
240	Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2015, 17, 1167-1172.	2.6	20
241	Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers. <i>JAMA Network Open</i> , 2018, 1, e181346.	5.9	20
242	Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. <i>PLoS ONE</i> , 2019, 14, e0210104.	2.5	20
243	Ubiquitous atmospheric contamination by tobacco smoke: Nicotine and a new marker for tobacco smoke-derived particulate matter, nicotelline. <i>Environment International</i> , 2021, 150, 106417.	10.0	20
244	The Impact of Exclusive Use of Very Low Nicotine Cigarettes on Compensatory Smoking: An Inpatient Crossover Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 880-886.	2.5	20
245	Effect of Disulfiram on Cognition, Subjective Response, and Cortical-Related Potentials in Nonalcoholic Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 1979, 3, 223-229.	2.4	19
246	Nicotine-mecamylamine interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 58-66.	4.7	19
247	Systemic Nicotine Exposure in Tobacco Harvesters. <i>Archives of Environmental Health</i> , 2001, 56, 257-263.	0.4	19
248	Acute Effect of Hookah Smoking on the Human Coronary Microcirculation. <i>American Journal of Cardiology</i> , 2016, 117, 1747-1754.	1.6	19
249	High Carbon Monoxide Levels from Charcoal Combustion Mask Acute Endothelial Dysfunction Induced by Hookah (Waterpipe) Smoking in Young Adults. <i>Circulation</i> , 2019, 139, 2215-2224.	1.6	19
250	Brain Phenobarbital Uptake during Prolonged Status Epilepticus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987, 7, 783-788.	4.3	18
251	Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 143-154.	1.5	18
252	Reprint of: Prevention and Treatment of Tobacco Use. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2964-2979.	2.8	18



#	ARTICLE	IF	CITATIONS
253	Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 172-176.	1.5	17
254	Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017, 26, e43-e48.	3.2	17
255	Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019, 21, S63-S72.	2.6	17
256	The Role of Compensation in Nicotine Reduction. <i>Nicotine and Tobacco Research</i> , 2019, 21, S16-S18.	2.6	17
257	Biomarkers of Exposure for Dual Use of Electronic Cigarettes and Combustible Cigarettes: Nicotelline, NNAL, and Total Nicotine Equivalents. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1107-1113.	2.6	17
258	Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 871-879.	2.5	17
259	Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S18-S36.	2.0	17
260	The biology of nicotine dependence: From the 1988 Surgeon General's Report to the present and into the future. <i>Nicotine and Tobacco Research</i> , 1999, 1, 159-163.	2.6	16
261	<i>CHRNA</i> genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. <i>Addiction</i> , 2013, 108, 1818-1828.	3.3	16
262	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial of Cytisinicline in Adult Smokers (The ORCA-1 Trial). <i>Nicotine and Tobacco Research</i> , 2021, 23, 1656-1663.	2.6	16
263	A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2016, 47, 12-21.	1.8	15
264	Effect of $\gamma$ -hydroxybutyrate (GHB) on driving as measured by a driving simulator. <i>Psychopharmacology</i> , 2018, 235, 3223-3232.	3.1	15
265	Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1083-1090.	2.5	15
266	Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. <i>Journal of General Internal Medicine</i> , 2019, 34, 862-870.	2.6	15
267	Identification and quantification of electronic cigarette exhaled aerosol residue chemicals in field sites. <i>Environmental Research</i> , 2019, 170, 351-358.	7.5	15
268	Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 975-985.	4.7	15
269	Thirdhand smoke associations with the gut microbiomes of infants admitted to a neonatal intensive care unit: An observational study. <i>Environmental Research</i> , 2021, 197, 111180.	7.5	15
270	Tobacco-free Nicotine – New Name, Same Scheme?. <i>New England Journal of Medicine</i> , 2021, 385, 2406-2408.	27.0	15



#	ARTICLE	IF	CITATIONS
271	Workshop on Problem-Based Learning as a Method for Teaching Clinical Pharmacology and Therapeutics in Medical School. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 779-797.	2.0	14
272	How Toxic is Cocaine?. <i>Novartis Foundation Symposium</i> , 1992, 166, 125-148.	1.1	14
273	Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation. <i>Preventive Medicine</i> , 2018, 117, 5-7.	3.4	14
274	Impact of early nausea on varenicline adherence and smoking cessation. <i>Addiction</i> , 2020, 115, 134-144.	3.3	14
275	Twenty-Four-Hour Cardiovascular Effects of Electronic Cigarettes Compared With Cigarette Smoking in Dual Users. <i>Journal of the American Heart Association</i> , 2020, 9, e017317.	3.7	14
276	Differences in exposure to toxic and/or carcinogenic volatile organic compounds between Black and White cigarette smokers. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2021, 31, 211-223.	3.9	14
277	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. <i>Nicotine and Tobacco Research</i> , 2022, 24, 3-9.	2.6	14
278	The Healing and Empowering Alaskan Lives Toward Healthy-Hearts (HEALTHH) Project: Study protocol for a randomized controlled trial of an intervention for tobacco use and other cardiovascular risk behaviors for Alaska Native People. <i>Contemporary Clinical Trials</i> , 2018, 71, 40-46.	1.8	13
279	Quantitative biochemical screening for marijuana use and concordance with tobacco use in urban adolescents. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107583.	3.2	13
280	Biomarker feedback intervention for smoking cessation among Alaska Native pregnant women: Randomized pilot study. <i>Patient Education and Counseling</i> , 2019, 102, 528-535.	2.2	13
281	Twenty-Four-Hour subjective and pharmacological effects of adâ€libitum electronic and combustible cigarette use among dual users. <i>Addiction</i> , 2020, 115, 1149-1159.	3.3	13
282	Diazepam kinetics in acute alcohol withdrawal. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 832-836.	4.7	12
283	E-Hookah Versus E-Cigarettes: Findings From Wave 2 of the PATH Study (2014â€“2015). <i>American Journal of Preventive Medicine</i> , 2019, 57, e163-e173.	3.0	12
284	Nicotine Intake, Dependence, and Characteristics of Electronic Cigarette and Dual Users. <i>Tobacco Regulatory Science</i> (discontinued), 2019, 5, 27-35.	0.2	12
285	Secondhand Tobacco Smoke Exposure Among Hospitalized Nonsmokers With Coronary Heart Disease. <i>JAMA Internal Medicine</i> , 2015, 175, 133.	5.1	11
286	Sources and Biomarkers of Secondhand Tobacco Smoke Exposure in Urban Adolescents. <i>Academic Pediatrics</i> , 2020, 20, 493-500.	2.0	11
287	Mouth-Level Nicotine Intake Estimates from Discarded Filter Butts to Examine Compensatory Smoking in Low Nicotine Cigarettes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 643-649.	2.5	11
288	â€œI actually finally feel like the cigarettes arenâ€™t controlling me.â€ Interviews with participants smoking very low nicotine content cigarettes during a residential study. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108465.	3.2	11

#	ARTICLE	IF	CITATIONS
289	Fetal Exposure to Carcinogens With Tobacco Use in Pregnancy: Phase 1 MAW Study Findings. <i>Nicotine and Tobacco Research</i> , 2016, 18, 2162-2168.	2.6	10
290	Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. <i>PLoS ONE</i> , 2019, 14, e0215853.	2.5	10
291	Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 223-232.	1.8	10
292	The Central Role of pH in the Clinical Pharmacology of Nicotine: Implications for Abuse Liability, Cigarette Harm Reduction and FDA Regulation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1004-1006.	4.7	10
293	Birthing of clinical pharmacologists*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 587-591.	4.7	9
294	The Use of Hemodialysis and Hemoperfusion in the Treatment of Theophylline Intoxication. <i>Seminars in Dialysis</i> , 1993, 6, 243-252.	1.3	9
295	Different profiles of carcinogen exposure in Chinese compared with US cigarette smokers. <i>Tobacco Control</i> , 2015, 24, e258-e263.	3.2	9
296	Seizures After Vaping Nicotine in Youth: A Canary or a Red Herring?. <i>Journal of Adolescent Health</i> , 2020, 66, 1-2.	2.5	9
297	Cigarette Smoke Exposure and Acute Respiratory Distress Syndrome in Sepsis: Epidemiology, Clinical Features, and Biologic Markers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 927-935.	5.6	9
298	Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2201.	7.4	9
299	Carbon monoxide, cigarette smoking and CYP2E1 activity. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 154-154.	4.7	8
300	Nicotine Addiction: Mechanisms and Consequences. <i>International Journal of Mental Health</i> , 2011, 40, 22-38.	1.3	8
301	Comprehensive Parentâ€™Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1119-1134.	3.5	8
302	Cigarette Smoking and ARDS After Blunt Trauma. <i>Chest</i> , 2020, 158, 1490-1498.	0.8	8
303	Functional characterization of novel rare <i>CYP2A6</i> variants and potential implications for clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 204-220.	3.1	8
304	Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. <i>Scientific Reports</i> , 2021, 11, 19572.	3.3	8
305	Minoxidil-Associated Pleuropericardial Effusion. <i>Journal of General Internal Medicine</i> , 2016, 31, 1105-1105.	2.6	7
306	Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency. <i>Drug and Alcohol Dependence</i> , 2017, 178, 267-270.	3.2	7

#	ARTICLE	IF	CITATIONS
307	Slower nicotine metabolism among postmenopausal Polish smokers. <i>Pharmacological Reports</i> , 2018, 70, 434-438.	3.3	7
308	Urine 4-(methylnitrosamino)-1-(3) pyridyl-1-butanol and cotinine in Alaska native postpartum women and neonates comparing smokers and smokeless tobacco users. <i>International Journal of Circumpolar Health</i> , 2018, 77, 1528125.	1.2	7
309	Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. <i>Journal of the National Medical Association</i> , 2019, 111, 509-520.	0.8	7
310	Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1196-1203.	4.7	7
311	Reductions in urinary metabolites of exposure to household air pollution in pregnant, rural Guatemalan women provided liquefied petroleum gas stoves. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2020, 30, 362-373.	3.9	7
312	Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. <i>Addiction</i> , 2021, 116, 2816-2824.	3.3	7
313	Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. <i>Drug and Alcohol Dependence</i> , 2021, 223, 108708.	3.2	7
314	Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users. <i>Nicotine and Tobacco Research</i> , 2016, 18, 366-370.	2.6	6
315	Perceived risks and reasons to smoke cigarettes during pregnancy among Alaska native women. <i>Ethnicity and Health</i> , 2018, 23, 33-42.	2.5	6
316	Managing Cannabis Use in Patients With Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2019, 35, 138-141.	1.7	6
317	Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 97-107.	1.5	6
318	Effects of Marijuana Use on Smokers Switching to E-Cigarettes in a Randomized Clinical Trial. <i>Nicotine and Tobacco Research</i> , 2022, 24, 994-1002.	2.6	6
319	Tobacco toxicant exposure in cigarette smokers who use or do not use other tobacco products. <i>Drug and Alcohol Dependence</i> , 2017, 179, 330-336.	3.2	5
320	Relationship between skin melanin index and nicotine pharmacokinetics in African American smokers. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107474.	3.2	5
321	E-cigarettes and dual nicotine replacement therapy for smoking cessation. <i>Lancet Respiratory Medicine</i> , 2020, 8, 7-8.	10.7	5
322	Relationships Between Race, Gender, and Spot Urine Levels of Biomarkers of Tobacco Exposure Vary Based on How Creatinine Is Handled in Analyses. <i>Nicotine and Tobacco Research</i> , 2020, 22, 2109-2113.	2.6	5
323	Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah Smoking. <i>American Journal of Cardiology</i> , 2020, 125, 1725-1731.	1.6	5
324	Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes. <i>Psychology of Addictive Behaviors</i> , 2022, 36, 100-108.	2.1	5

#	ARTICLE	IF	CITATIONS
325	Response to Letter Regarding Article, “Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease: A Randomized Trial” Circulation, 2010, 122, .	1.6	4
326	Urinary NNAL in hookah smokers and non-smokers after attending a hookah social event in a hookah lounge or a private home. Regulatory Toxicology and Pharmacology, 2017, 89, 74-82.	2.7	4
327	Another Article About “Cigarettes: Why Should I Care?”. Journal of the American Heart Association, 2018, 7, .	3.7	4
328	Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. Addiction, 2019, 114, 1824-1833.	3.3	4
329	Development and Piloting Testing of an Experimental Tobacco and Nicotine Product Marketplace. Nicotine and Tobacco Research, 2020, 22, 1230-1234.	2.6	4
330	Australian smokers’ experiences and perceptions of recessed and firm filter cigarettes. Tobacco Control, 2021, 30, 660-667.	3.2	4
331	3-Ethenylpyridine Measured in Urine of Active and Passive Smokers: A Promising Biomarker and Toxicological Implications. Chemical Research in Toxicology, 2021, 34, 1630-1639.	3.3	4
332	Cultural and demographic correlates of dual tobacco use in a sample of Alaska Native adults who smoke cigarettes. Tobacco Induced Diseases, 2020, 18, 55.	0.6	4
333	Chronic Disease Management Approach to Treating Tobacco Addiction. Archives of Internal Medicine, 2011, 171, 1907.	3.8	3
334	Biomarkers of Exposure to Nicotine and Tobacco-Specific Nitrosamines in Adolescent Blunt Users. Nicotine and Tobacco Research, 2020, 22, 1428-1429.	2.6	3
335	Effects of Nicotine Metabolic Rate on Cigarette Reinforcement. Nicotine and Tobacco Research, 2020, 22, 1419-1423.	2.6	3
336	Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy. , 2021, , 97-117.		3
337	Does sex alter the relationship between <i>CYP2B6</i> variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis. Addiction, 2022, 117, 1715-1724.	3.3	3
338	Associations of Smokeless Tobacco Use With Cardiovascular Disease Risk: Insights From the Population Assessment of Tobacco and Health Study. Nicotine and Tobacco Research, 2022, 24, 1063-1070.	2.6	3
339	Stimulant drugs are associated with violent and penetrating trauma. American Journal of Emergency Medicine, 2019, 37, 645-650.	1.6	2
340	Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day). Clinical Toxicology, 2019, 57, 1123-1124.	1.9	2
341	Exposure to a Tobacco-Specific Carcinogen Among Adolescent Smokeless Tobacco Users in Rural California, United States. Nicotine and Tobacco Research, 2020, 22, 1764-1771.	2.6	2
342	The influence of nicotine metabolic rate on working memory over 6 hours of abstinence from nicotine. Pharmacology Biochemistry and Behavior, 2020, 188, 172836.	2.9	2

#	ARTICLE	IF	CITATIONS
343	Comparison of smoking cessation rates of Quitline users in Korea between smokers of ultra-low nicotine yield cigarettes and other types of cigarette: a prospective study. <i>Addiction</i> , 2020, 115, 1745-1753.	3.3	2
344	Correlates of the nicotine metabolite ratio in Alaska Native people who smoke cigarettes.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 359-364.	1.8	2
345	Neurobiology of Nicotine and Tobacco. , 2021, , .		2
346	Pharmacogenetics of Nicotine Metabolism in Twins: Methods and Procedures. <i>Twin Research and Human Genetics</i> , 2004, 7, 435-448.	1.0	2
347	Determination of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone (NNK) arising from tobacco smoke in airborne particulate matter. <i>Environment International</i> , 2022, 158, 106992.	10.0	2
348	Tobacco-specific and combustion pollutants in settled house dust in Malta. , 2022, 1, .		2
349	Maternal nicotine metabolism moderates the impact of maternal cigarette smoking on infant birth weight: A Collaborative Perinatal Project investigation. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109358.	3.2	2
350	Diabetic Patients and Hepatic Drug Metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 695-694.	4.7	1
351	Recruitment best practices of a cardiovascular risk reduction randomised control trial in rural Alaska Native communities. <i>International Journal of Circumpolar Health</i> , 2020, 79, 1806639.	1.2	1
352	Evaluation of nicotine patch adherence measurement using self-report and saliva cotinine among abstainers in a smoking cessation trial. <i>Drug and Alcohol Dependence</i> , 2020, 210, 107967.	3.2	1
353	Disposition kinetics and effects of menthol. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 128-135.	4.7	1
354	Saliva cotinine levels as a function of collection method. <i>Addiction</i> , 1997, 92, 347-352.	3.3	1
355	A Mobile Health Intervention for Adolescents Exposed to Secondhand Smoke: Pilot Feasibility and Efficacy Study. <i>JMIR Formative Research</i> , 2020, 4, e18583.	1.4	1
356	Relations among cigarette dependence, e-cigarette dependence, and key dependence criteria among dual users of combustible and e-cigarettes. <i>Psychology of Addictive Behaviors</i> , 2020, , .	2.1	1
357	Balfour et al. Respond. <i>American Journal of Public Health</i> , 2022, 112, e2-e3.	2.7	1
358	Early Changes in Puffing Intensity When Exclusively Using Open-Label Very Low Nicotine Content Cigarettes. <i>Nicotine and Tobacco Research</i> , 2022, , .	2.6	1
359	Minor Tobacco Alkaloids as Biomarkers to Distinguish Combusted Tobacco Use From Electronic Nicotine Delivery Systems Use. Two New Analytical Methods. <i>Frontiers in Chemistry</i> , 2022, 10, .	3.6	1
360	“You have the right to protect your health” Perceptions of Secondhand Smoke and Exposure Mitigation Strategies in Low-Income Patients With Heart Disease, San Francisco, 2011–2012. <i>Preventing Chronic Disease</i> , 2016, 13, E116.	3.4	0

#	ARTICLE	IF	CITATIONS
361	A mixed effects model for analyzing area under the curve of longitudinally measured biomarkers with missing data. Pharmaceutical Statistics, 2021, 20, 1249-1264.	1.3	0
362	Secondhand smoke exposure in school children in Malta assessed through urinary biomarkers. Environmental Research, 2021, 204, 112405.	7.5	0
363	Balfour etÂal. Respond. American Journal of Public Health, 2022, 112, e5-e6.	2.7	0
364	Nicotine Addiction and Its Treatment. , 2022, , 297-341.		0